CAR-T Puts Bowel Disease Into Remission

LondonChimeric antigen receptor T-cell therapy induced long-term remission in ulcerative colitis.

CD19-targeted cells reach the mucosal B cells driving colitis — reprogramming the immune loop that antibody drugs cannot break.

Researchers say controlled trials are needed to validate safety and efficacy before clinical adoption.

Sources: Nature